SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Eagle Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

LOS ANGELES--()--Goldberg Law PC ( announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

“cannot approve the application in its present form and requested additional information”

If you purchased or otherwise acquired Eagle shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at, or by email at

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s March 18, 2016, announcement that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO™.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at, or email us at

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Goldberg Law PC